NCT01284725|CompletedPhase 3
Weaning of Immunosuppression in Nephritis of Lupus
WIN-Lupus
Loading search results
WIN-Lupus
Sponsor study identifier
Secondary identifiers
OTHER · AP HM
interventional
100
1 country
1
Study Start
February 16, 2011
Actual (reported)Primary Completion
February 6, 2016
Actual (reported)Study Completion
December 31, 2018
Actual (reported)The investigators wish to evaluate the discontinuation of maintenance immunosuppressive treatment after 2 years in patients with stable remission after a proliferative lupus nephritis. The patients will be continuing their treatment with hydroxychloroquine, possibly associated with low dose corticosteroids.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 21, 2011
Actual (reported)January 27, 2011
Actual (reported)February 16, 2011
Actual (reported)February 6, 2016
Actual (reported)December 31, 2018
Actual (reported)discontinuation of maintenance immunosuppressive therapy
to demonstrate that discontinuation of maintenance immunosuppressive therapy does not expose patients to a greater risk of relapse of proliferative lupus nephritis compared to the continuation of this treatment
2 years
compare 2 therapeutic strategies
2 years
with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
mycophenolate mofetil or azathioprine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordAssistance Publique Hopitaux de Marseille
Marseille, 13354, France
Himbert M, Jourde-Chiche N, Chapart L, Charles N, Baumstarck K, Daugas E. Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse. RMD Open. 2024 Jun 28;10(2):e004255. doi: 10.1136/rmdopen-2024-004255.
Jourde-Chiche N, Bobot M, Burtey S, Chiche L, Daugas E. Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How? Kidney Int Rep. 2023 May 22;8(8):1481-1488. doi: 10.1016/j.ekir.2023.05.012. eCollection 2023 Aug.
BERNARD BELAIGUES
Assistance Publique hôpitaux de Marseille
NOEMIE JOURDE CHICHE
Assistance publique Hôpitaux de marseille
100 participants (actual enrollment reported by the registry).
First Submitted
January 21, 2011
First Posted
January 27, 2011
Study Start
February 16, 2011
Actual (reported)Contact the study team to confirm eligibility.
Jourde-Chiche N, Chiche L. An era of immunosuppressant withdrawal in systemic lupus erythematosus: winning through weaning. Lancet Rheumatol. 2024 Mar;6(3):e133-e134. doi: 10.1016/S2665-9913(24)00001-8. Epub 2024 Jan 29. No abstract available.
Chiche L, Jousse-Joulin S, Jourde-Chiche N. [From "Treat to Target" to "Think to Untreat": Therapeutic de-implementation as a new paradigm in systemic lupus erythematosus]. Rev Med Interne. 2023 Mar;44(3):101-104. doi: 10.1016/j.revmed.2022.12.001. Epub 2022 Dec 22. No abstract available. French.
Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, Caudwell V, Chiche L, Couzi L, Daniel L, Deligny C, Dussol B, Faguer S, Gobert P, Gondran G, Huart A, Hummel A, Kalbacher E, Karras A, Lambert M, Le Guern V, Lebourg L, Loubiere S, Maillard-Lefebvre H, Maurier F, Pha M, Queyrel V, Remy P, Sarrot-Reynauld F, Verhelst D, Hachulla E, Amoura Z, Daugas E; WIN-Lupus study group. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022 Oct;81(10):1420-1427. doi: 10.1136/annrheumdis-2022-222435. Epub 2022 Jun 20.
Primary Completion
February 6, 2016
Actual (reported)Study Completion
December 31, 2018
Actual (reported)Last Updated
September 18, 2025
Record last verified: 2025-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: